Table 1: Main demographic and clinical features of the two groups.

Variable
Danlou Tablet group
()
Placebo
group
()
() value

Age, yr0.040.44
Men, number (%)72 (66.1)74 (67.3)0.040.85
Body weight, kg0.55
Height, cm0.82
Family history of coronary disease, number (%)18 (16.5)10 (9.1)2.710.10
Concomitant diseases, number (%)
 Previous coronary heart disease41 (37.6)47 (42.7)0.600.44
 Previous coronary intervention9 (8.3)17 (15.5)2.710.10
 Systemic hypertension51 (46.8)63 (57.3)2.410.12
 Diabetes mellitus21 (19.3)19 (17.3)0.150.70
 Dyslipidemia38 (34.9)38 (34.5)0.0020.96
 Heart failure1 (0.9)4 (3.6)0.3
 Arrhythmia4 (3.7)10 (9.1)2.690.10
 Stroke7 (6.4)8 (7.3)0.060.80
Current smoker, number (%)47 (43.1)44 (40.0)0.220.64
Cardiac Marker Elevation, number (%)30 (27.5%)33 (30.0%)0.160.69
Clinical pattern, number (%)
 Unstable angina88 (80.7)87 (79.1)0.090.76
 NSTEMI21 (19.3)23 (20.9)
Cardiac function, number (%)
 Level I41 (37.6)41 (37.3)0.030.99
 Level II53 (48.6)53 (48.2)
 Level III15 (13.8)16 (14.5)

Values are given as number of patients (%) or mean ± SD. NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; ACE, angiotensin-converting enzyme; and ARB, angiotensin II receptor blocker. value is from Fisher’s exact test.